Photo from wikipedia
A major barrier to therapeutic development in neonates is a lack of standardized drug response measures that can be used as clinical trial endpoints. The ability to quantify treatment response… Click to show full abstract
A major barrier to therapeutic development in neonates is a lack of standardized drug response measures that can be used as clinical trial endpoints. The ability to quantify treatment response in a way that aligns with relevant downstream outcomes may be useful as a surrogate marker for new therapies, such as those for bronchopulmonary dysplasia (BPD).
Keywords:
corticosteroid response;
bronchopulmonary dysplasia;
response;
predicts bronchopulmonary;
response predicts
Journal Title: Pediatric Pulmonology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pediatric Pulmonology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!